Stockscreener 앱 받기
9.81
7.10%
0.65
시간 외 거래:
9.69
-0.12
-1.22%
전일 마감가:
$9.16
열려 있는:
$9.15
하루 거래량:
9.21M
Relative Volume:
1.92
시가총액:
$2.46B
수익:
$874.84M
순이익/손실:
$263.86M
주가수익비율:
8.1539
EPS:
1.2031
순현금흐름:
$327.41M
1주 성능:
+17.06%
1개월 성능:
+31.15%
6개월 성능:
+27.40%
1년 성능:
+28.57%
1일 변동 폭
$9.05
$9.975
1주일 범위
$8.15
$9.975
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.81 | 2.30B | 874.84M | 263.86M | 327.41M | 1.2031 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 재개 | Evercore ISI | Outperform |
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Insider Monkey
BioCryst Takeover Rumors Test Investor Focus On Fundamentals And Optionality - Yahoo Finance
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals: Why This $2B Drugmaker Is Suddenly On Big Pharma’s Radar! - Smartkarma
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock - MarketBeat
BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares - Investing.com
BioCryst (BCRX) CLO sells 150K shares after option exercise - Stock Titan
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its Profitability And Revenue Turnaround - Sahm
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real (NASDAQ:BCRX) - Seeking Alpha
BioCryst (BCRX) Soars 13% on Acquisition Buzz - Insider Monkey
BioCryst Pharmaceuticals Stock Jumps 13.8% - National Today
10 Stocks Worth Watching Right Now: Tencent, Circle, BioCryst and More - Insider Monkey
BioCryst Pharmaceuticals jumps as investors revisit profitable 2025 results, upbeat HAE pipeline data, and potential short-covering dynamics - Quiver Quantitative
Form 144 resale notice lists 150,000 shares (NASDAQ: BCRX) - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8%Here's What Happened - MarketBeat
BioCryst Pharmaceuticals Sees Profitable Quarter Amid Strategic Moves - StocksToTrade
Top Biotech Stocks To Keep An Eye OnMarch 16th - MarketBeat
BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition - timothysykes.com
BioCryst gains amid takeover speculation - MSN
BioCryst Pharmaceuticals (BCRX) Surges 15% Amid Takeover Specula - GuruFocus
BioCryst Stock Surges on Profit Milestone and Upgrades - TipRanks
Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Whale Trades: Will BioCryst Pharmaceuticals Inc benefit from green energy policiesMarket Activity Recap & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances - MSN
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC - MarketBeat
BCRXBioCryst Reports Full Year 2025 Financial Results and Provides Business Update - mx.advfn.com
Evercore ISI sees long-term growth potential for BioCryst Pharmaceuticals, Inc. (BCRX) following Astria acquisition - MSN
BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline - MarketBeat
BioCryst Pharmaceuticals Hits Day High with Strong 10.76% Intraday Surge - Markets Mojo
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Fisher Asset Management LLC - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
BioCryst (BCRX) Grants Stock Units to New Employees - GuruFocus
Director Jill C. Milne receives 528 BCRX shares as board retainer grant - Stock Titan
Biocryst (NASDAQ: BCRX) director executes option exercise and share disposition - Stock Titan
Director Vincent Milano gets 848 BIOCRYST (BCRX) shares as equity retainer - Stock Titan
BIOCRYST (BCRX) director Steven Frank receives 1,285-share stock retainer grant - Stock Titan
Director Amy McKee receives stock retainer award at BioCryst (BCRX) - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 146.81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects - Investing.com
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio ExpansionHas The Bull Case Changed? - Sahm
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com India
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioCryst Pharmaceuticals, Inc. $BCRX Stock Holdings Boosted by Vanguard Group Inc. - MarketBeat
BioCryst Pharmaceuticals Receives $19.64 Consensus Price Target - National Today
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next - TechStock²
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):